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Prospective Validation
of the Prognostic Usefulness
of Brain Natriuretic Peptide in Asymptomatic
Patients With Chronic Severe Mitral Regurgitation
Rodolfo Pizarro, MD, Oscar O. Bazzino, MD, Pablo F. Oberti, MD, Mariano Falconi, MD,
Federico Achilli, MD, Anibal Arias, MD, Juan G. Krauss, MD, Arturo M. Cagide, MD
Buenos Aires, Argentina
Objectives The purpose of the study was to determine the independent and additive prognostic value of brain natriuretic
peptide (BNP) in patients with severe asymptomatic mitral regurgitation and normal left ventricular function.
Background Early surgery could be advisable in selected patients with chronic severe mitral regurgitation, but there are no
criteria to identify candidates who could benefit from this strategy. Assessment of BNP has not been studied in
asymptomatic patients with severe mitral regurgitation; hence, its prognostic value remains unclear.
Methods We prospectively evaluated 269 consecutive patients with severe asymptomatic organic mitral regurgitation and
left ventricular ejection fraction above 60%. The first 167 consecutive patients served as the derivation cohort,
and the following 102 patients served as a validation cohort. The combined end point was the occurrence of
either symptoms of congestive heart failure, left ventricular dysfunction, or death at follow-up.
Results The end point was reached in 35 (21%) patients of the derivation set and in 21 (20.6%) patients of the validation
cohort. The receiver-operating characteristics curve yielded an optimal cutoff point of 105 pg/ml of BNP that was able
to discriminate patients at higher risk in both cohorts (76% vs. 5.4% and 66% vs. 4.0%, respectively). In both sets,
BNP was the strongest independent predictor by multivariate analysis.
Conclusions Among patients with severe asymptomatic organic mitral regurgitation, BNP 105 pg/ml discriminates a sub-
group of patients at higher risk. Because of its incremental prognostic value, BNP assessment should be consid-
ered in clinical routine workup for risk stratification. (J Am Coll Cardiol 2009;54:1099–106) © 2009 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.06.013d
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levere organic mitral regurgitation is a progressive disease
ith a high incidence of events in the long-term follow-up
1–4). Usually, surgical treatment is recommended based on
he presence of symptoms of congestive heart failure
CHF), the appearance of left ventricular dysfunction, and
ess frequently, because of the amount of regurgitation
1,2,5). In contrast, the indication of early surgical treat-
ent in patients suitable for this intervention, but who do
ot have symptoms of heart failure or left ventricular
ysfunction, is controversial. In this particular subset of
atients, there are no strong indicators useful for the
ecommendation of early surgical intervention.
rom the Cardiology Division, Hospital Italiano de Buenos Aires, Buenos Aires,
rgentina.a
Manuscript received February 25, 2009; revised manuscript received May 6, 2009,
ccepted June 1, 2009.For this purpose, the prognostic value of several echocar-
iographic parameters has been assessed in different studies.
pecifically, end-systolic diameter and left atrial size, as well
s both ejection fraction and ventricular size, have been
ound to allow risk stratification in asymptomatic patients
5–7). Another marker of hemodynamic consequences, the
ffective regurgitant orifice area (EROA), has also been
hown to correlate with an adverse outcome (7,8).
See page 1107
In recent years (9–11), the measurement of natriuretic
eptides in patients with heart failure has become impor-
ant. The brain natriuretic peptide (BNP) and its inactive
mino-terminal portion (NT-proBNP), both result from
he breakdown of proBNP. These hormones have vasodi-
ator and diuretic effects, are antagonists of the adrenergic
nd renin-angiotensin systems, and are released in response
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BNP and Asymptomatic Severe MR September 15, 2009:1099–106to an increase in myocardial wall
stress (1). The prognostic value
of natriuretic peptides has been
assessed in patients with valve
disease with inconsistent results
and without information regard-
ing clinical and echocardio-
graphic data (9–11).
In addition, no further work
has been done to integrate the
clinical, echocardiographic, and
biochemistry data to allow for a
better understanding of the func-
tional status and of both short-
and long-term risk.
Hence, the purpose of this in-
vestigation was to determine the
additional prognostic value of
baseline BNP in asymptomatic
patients with severe organic mi-
tral regurgitation and no left ven-
tricular dysfunction. Our goal
was also to validate prospectively
a cutoff point value of BNP for
he prediction of an adverse outcome and to assess the
rognostic significance of the changes in the BNP level
bserved between baseline and 1 year of follow-up.
ethods
tudy population. In this single-center study, we prospectively
valuated 269 consecutive patients with severe asymptomatic
rganic mitral regurgitation and normal left ventricular perfor-
ance (ejection fraction above 60%).
Applying a splitting technique, the first 167 consecutive
atients were analyzed as the derivation set of data (mean
ge: 63  7 years; 63% men, mean ejection fraction: 67 
%) and the next 102 consecutive patients as the validation
et (mean age: 66  8 years, 63% men, mean ejection
raction: 66  5%). In the derivation set, the etiology of the
itral regurgitation was degenerative in 148 patients, rheu-
atic in 13, and post-endocarditis in 6 patients. In the
alidation set, these etiologies were observed in 89, 9, and 4
atients, respectively.
We included patients fulfilling the following 2 criteria:
. Severe mitral regurgitation as determined by echocardio-
graphic measurement (effective regurgitant orifice area
[EROA]) 40 mm2 and regurgitant volume 60 ml/
beat) (12).
. Preserved exercise tolerance defined by an exercise elec-
trocardiogram with Bruce protocol and the following
requirements: functional capacity 7 metabolic equiva-
lents of task (METs) without symptoms or any of the
following: complex ventricular arrhythmia, hypotension,
Abbreviations
and Acronyms
AV  atrial volume
BNP  brain natriuretic
peptide
BSA  body surface area
CHF  congestive heart
failure
CI  confidence interval
EROA  effective
regurgitant orifice area
HR  hazard ratio
LVDSD  left ventricular
dysfunction, symptoms of
congestive heart failure, or
death
NFL  new flail leaflet
NYHA  New York Heart
Association
OR  odds ratio
ROC  receiver-operating
characteristicor pathological ST-T segment deviation (8). cWe excluded patients with associated valve disease (aortic
alve disease, moderate or severe mitral stenosis, or signif-
cant right organic valve disease), ischemic mitral regurgi-
ation, previous valve or coronary surgery, cardiomyopathies
r pericardial diseases, patients with terminal disease whose
xpected survival was 1 year, patients with poor echocar-
iographic acoustic window, and those who did not com-
lete the initial exercise test requirements.
Follow-up was complete in all but 6 cases (4 patients of
he derivation set and 2 patients of the validation set).
linical data. At entry, complete clinical evaluation was
erformed in all patients. Decisions about valve surgery
ere left to the treating physicians, who were unaware of the
NP results.
chocardiographic data. All studies were performed with
ewlett Packard Sonos 5500 equipment (Andover, Massa-
husetts). Studies included a spectral, continuous, and color
oppler transthoracic echocardiographic examination in all
atients. The degree of mitral regurgitation was quantified
n relation to the classical color Doppler parameters (12).
Left ventricular volumes and left ventricular ejection
raction were measured by Simpson’s biplane technique
13). End-diastolic and -systolic diameters were indexed by
ody surface area (BSA) (end-diastolic diameter/BSA and
nd-systolic diameter/BSA) (14). Atrial volume (AV) was
ndexed by BSA (AV/BSA), and pulmonary artery systolic
ressures were measured classically. The presence of a new
ail leaflet (NFL) was also assessed (14–16).
We measured regurgitant volume, regurgitant fraction,
nd EROA (as an average of the quantitative method, and
he proximal isovelocity area method, PISA) (17,18).
The echocardiographic readings were carried out by 2
ndependent observers, who were blinded to the clinical and
iochemistry information.
iochemistry data. Blood samples were obtained in all
atients 24 h after enrollment in the echocardiography
aboratory and repeated 1 year later. Venous blood samples
ere obtained on usual medications with the patient resting
uietly while semirecumbent. The samples were placed imme-
iately on ice, and plasma was stored at 80°C before being
ssayed for BNP using standard radioimmunoassay (19).
nd point definition. The combined end point consisted
f the appearance of either CHF or left ventricular dysfunc-
ion, or the occurrence of death (LVDSD) during follow-
p. The presence of CHF was defined as the onset of
yspnea in New York Heart Association (NYHA) func-
ional class III to IV, requiring sustained pharmacologic
reatment or hospitalization.
New onset of left ventricular dysfunction was defined as
he assessment of an ejection fraction below 60% (7,9)
uring follow-up.
All outcomes were assessed by 2 investigators blinded to
he echocardiographic clinical data. Patients referred for
urgery without symptoms or low ejection fraction (deci-
ions regarding surgery left to treating physician) were
ounted as not reaching an end point in the analysis.
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September 15, 2009:1099–106 BNP and Asymptomatic Severe MRollow-up. Clinical and echocardiographic evaluations
ere performed at least yearly during a follow-up visit.
atients who died or underwent surgery were censored the
ame day, and those who remained alive were censored at
he end of follow-up.
tatistical analysis. All results for continuous variables are
xpressed as mean SD, and skewed variables are expressed as
edian and interquartile range (IQR). For groupwise compar-
sons of continuous variables, the Mann-Whitney U and
tudent t tests were used for skewed and normally distributed
ariables, respectively. For categorical variables, the Fisher
xact test or the chi-square test were used. The cutoff level for
ach echocardiographic variable was obtained from previous
tudies (7). The cutoff level for METs, AV/BSA, and ejection
raction were set according to the receiver-operating character-
stic (ROC) curve analysis.
The cutoff level for BNP was set according to the ROC
urve analysis. The BNP value showing the maximum
ikelihood ratio in the curve was established as the cutoff
oint between low and high BNP. This cutoff point was
rospectively tested in the validation set.
Survival analysis was assessed using the Kaplan-Meier
ethod. Nonadjusted comparison of time to the event was
ased on the log-rank test.
Logistic regression models were developed to analyze
he effect of clinical and echocardiographic variables on
he observed association between basal BNP levels and
he risk of the combined end point. For the assessment of
inearity, we grouped BNP concentrations and the echo-
ardiographic variables into quartiles. Then we fitted a
ogistic regression model for the prediction of the com-
ined end point, with the lowest quartile serving as the
eference group, and plotted the average value of each
asal Characteristics in Relation to BNP LevelsTable 1 Basal Characteristics in Relation to BNP Levels
Derivation S
BNP <105 pg/ml
(n  130)
BNP >1
(n 
Age (yrs) 61 6 66
Male 77 (59) 24 (
Atrial fibrillation 12 (9) 5 (
Hypertension 20 (15) 8 (
Systolic arterial pressure (mm Hg) 139 22 (93–170) 135 1
Heart rate (beats/min) 76 10 (62–98) 69 1
NFL, n (%) 2 (1.5) 4 (
Exercise capacity (METs) 9.5 (8.5–11) 9.0 (
Ejection fraction (%) 68 (65–72) 65 (
End-diastolic diameter/BSA (mm/m2) 33 (25–38) 40 (2
End-systolic diameter/BSA (mm/m2) 18 (14–23) 24 (1
Regurgitant volume (ml/beat) 65 (63–70) 76 (6
Regurgitant fraction (%) 49 (46–55) 58 (4
EROA (mm2) 53 (46–61) 65 (4
AV/BSA (cm3/m2) 65 (42–73) 76 (4
Pulmonary artery systolic pressure (mm Hg) 24 (18–30) 32 (2alues are expressed as mean  SD, n (%), or median (interquartile range).
AV  atrial volume; BNP  brain natriuretic protein; BSA  body surface area; EROA  effective reguuartile versus the coefficient of the quartile. The plot
as then examined with respect to the shape of the
esulting curve. Variables showing lack of linearity were
ogarithmically transformed.
The multivariate logistic regression models incorporated
linical and echocardiographic variables that proved to be
elated to the combined end point on univariate analysis.
To assess the statistical significance of BNP values, we
djusted the p values using the Bonferroni correction,
ividing the usual statistically significant p value (0.05) by
he number of variables in the model.
To facilitate the clinical interpretation, we repeated the
ultivariate analysis entering BNP and the echocardio-
raphic measurements as dichotomous variables with the
utoff points that were previously described.
Calibration and discrimination of the logistic models
ere tested with the Hosmer-Lemeshow test and compar-
son of the ROC curves of the derivation and validation sets.
Comparison between ROC curves was performed with
he ROC analyzer program version 6.0.
The statistical analysis was performed with STATA version
.0 software (College Station, Texas). A p value 0.05 was
onsidered significant, and all tests performed were 2-tailed.
esults
aseline characteristics. A total of 269 patients were in-
luded, 167 in the derivation cohort and 102 in the validation
ohort. Median BNP values (IQR 25% to 75%) at entry were
imilar in both sets, 21 (IQR 9 to 247) and 27 (IQR 7 to 241)
n the derivation and validation cohorts, respectively. The areas
f the ROC curves relating baseline BNP levels to the
ombined end point were 0.80 0.05 and 0.81 0.04 in the
Validation Set
/ml
p Value
BNP <105 pg/ml
(n  75)
BNP >105 pg/ml
(n  27) p Value
0.07 62 5 65 7 0.09
0.38 47 (63) 18 (65) 0.94
0.17 5 (6.6) 3 (7.4) 0.77
0.22 9 (12) 3 (10) 0.82
155) 0.27 137 28 (91–160) 136 21 (90–150) 0.77
89) 0.15 75 10 (60–101) 70 12 (55–94) 0.45
0.001 1 (1.3) 1 (3.7) 0.02
) 0.39 9.0 (8.0–14) 8.5 (7.5–11) 0.45
) 0.04 68 (65–70) 66 (63–69) 0.04
) 0.08 32 (24–37) 39 (31–45) 0.09
) 0.001 18 (14–22) 25 (21–30) 0.01
) 0.01 66 (62–71) 76 (68–86) 0.01
) 0.01 49 (45–57) 60 (52–67) 0.01
) 0.0001 46 (44–57) 67 (49–81) 0.001
) 0.03 64 (40–69) 77 (48–82) 0.02
) 0.04 25 (15–29) 35 (22–39) 0.037et
05 pg
37)
 8
64)
13)
21)
8 (90–
1 (55–
10)
8.0–12
63–68
9–46
9–29
6–84
9–64
7–74
9–84
4–38rgitant orifice area; METs  metabolic equivalents of task; NFL  new flail leaflet.
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BNP and Asymptomatic Severe MR September 15, 2009:1099–106erivation and validation cohorts, respectively. From the ROC
urve of the derivation set, we were able to derive an optimal
utoff value of 105 pg/ml. The highest likelihood ratio corre-
ponding to that value was 5.7 (95% confidence interval [CI]:
.9 to 10.6). In the ROC curve of the validation set, a BNP
alue of 105 pg/ml was also associated with the best likelihood
atio of the combined end point.
Baseline characteristics of patients according to BNP
evels at admission are compared in Table 1. No significant
ifferences were observed between both sets regarding age,
ex, hypertension, atrial fibrillation, heart rate, exercise
apacity, or end-diastolic diameter/BSA. In both sets,
atients with a baseline BNP level above 105 pg/ml had a
ignificantly higher rate of NFL, larger left ventricular
nd-systolic diameter and left atrial size, and higher pulmo-
ary artery pressure. All parameters related to the amount of
itral regurgitation, such as regurgitant volume, regurgitant
raction, and EROA, were also significantly higher in
atients with elevated BNP in the derivation as well as in
he validation set.
vents. In the derivation set, 35 patients (21%) reached
VDSD. Death occurred in 4 patients (2.4%); it was
udden in 2 patients, due to congestive heart failure in 1
atient, and of noncardiac cause in the remainder. New
HF was diagnosed in 27 patients (17%). Among these 27
atients, 18 received sustained pharmacologic treatment for
HF, and 10 patients required hospitalization for the same
eason. Seven patients (4.2%) developed left ventricular
ysfunction. Stable NYHA functional class II dyspnea
ccurred in 6 patients (3.6%), 7 patients (4.2%) had new-
nset atrial fibrillation, and 13 patients (7.8%) developed
ulmonary hypertension. Mean follow-up of the derivation
et was 36  8 months.
Mitral valve surgery was performed in 46 (27.5%) pa-
ients. Twenty-seven patients (59%) underwent mitral valve
epair, and 19 patients (41%) had mitral valve replacement.
hirty-two patients underwent surgery because of CHF or
eft ventricular systolic dysfunction. Fourteen patients did
ot reach the combined end point but underwent surgery, as
t was indicated by their referring physician. These patients
ere not significantly different from patients who reached
he combined end point regarding their clinical and echo-
ardiographic variables. BNP in this subset of 14 patients
as median 35 pg/ml (IQR 14 to 91 pg/ml).
In the validation set, 21 patients (20.6%) developed
VDSD. Death occurred in 2 patients (1.96%); it was
udden in 1 patient and noncardiac in another. In addition,
6 patients (15.7%) had CHF (10 patients received sus-
ained pharmacologic treatment for CHF, and 6 patients
ere hospitalized for the same reason). Finally, 4 patients
3.9%) developed left ventricular dysfunction. Mean
ollow-up in the validation set was 31  9 months. Stable
YHA functional class II dyspnea occurred in 4 patients
3.9%), 5 patients (4.9%) experienced new-onset atrial
brillation, and 10 patients (9.8%) developed pulmonary
ypertension during follow-up.Mitral valve surgery was performed in 30 patients (29%)
f the validation set. Nineteen patients (63%) underwent
itral valve repair and 11 patients (37%) mitral valve
eplacement. Eleven patients did not reach the combined
nd point but underwent surgery, as indicated by their
eferring physician. These patients were not significantly
ifferent with regard to clinical and echocardiographic
ariables from patients who reached the combined end
oint, and the median BNP value of these 11 patients was
9 (IQR 21 to 93).
redictive value of BNP. UNIVARIATE ANALYSIS. When
e stratified BNP according to quartiles: 20, 21 to 69, 70
o 104, and 105 pg/ml, patients’ event-free survival at 48
onths was as follows: 99  4%, 97  7%, 93  6%, and
9  8%, respectively. BNP values were higher in patients
eaching LVDSD in both the derivation (median 117, IQR
7 to 194 vs. median 38, IQR 19 to 67, p  0.001) and the
alidation sets (median 114, IQR 79 to 187 vs. median 35,
QR 20 to 64).
The rate of the combined end point was higher in
atients with BNP 105 pg/ml than in patients with BNP
105 pg/ml in the derivation set (76% vs. 5.4%; p 
.00001, Fisher exact test) and also in the validation set
66% vs. 4%; p  0.00001, Fisher exact test) (Fig. 1).
In the Kaplan-Meier analysis, BNP values were dichot-
mized at this cutoff point, and they were able to discrim-
nate patients with a higher risk of LVDSD in the deriva-
ion set (log-rank: 16.2, adjusted hazard ratio [HR]: 5.6;
5% CI: 2.9 to 10.6, p  0.0001) and also in the validation
et (log-rank: 13.2, adjusted HR: 4.7; 95% CI: 2.4 to 11.3,
 0.0001) (Figs. 2A and 2B).
Applying this cutoff value, sensitivity, specificity, negative
redictive value, and positive predictive value to predict
VDSD in the derivation set were 80%, 93%, 94%, and
Figure 1 Combined End Point According to BNP Values
Symptoms of congestive heart failure, left ventricular systolic dysfunction,
or death (LVDSD) according to brain natriuretic peptide (BNP) values.
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September 15, 2009:1099–106 BNP and Asymptomatic Severe MR6%, respectively, whereas in the validation set, values were
5%, 89%, 96%, and 66%, respectively.
Table 2 shows the relationship between baseline variables
nd prognosis. In both sets, univariate markers of worse
volution were BNP, end-systolic diameter/BSA, end-
iastolic diameter/BSA, EROA, regurgitant volume AV/
SA, age, pulmonary artery systolic pressures, atrial fibril-
ation, ejection fraction, and NFL.
ULTIVARIATE ANALYSIS. In the derivation set, all variables
ignificantly associated with the end point were included in
logistic regression analysis. In our first model, we used log
ransformation of the continuous variables. In the deri-
ation cohort, the independent predictors were: BNP
odds ratio [OR]: 3.89; 95% CI: 2.52 to 17.57, p 
.0001), end-systolic diameter/BSA (OR: 3.14; 95% CI:
.82 to 15.92, p  0.01), and EROA (OR: 3.57; 95% CI:
.27 to 16.45, p  0.001).
Figure 2 Survival Free of LVDSD According to BNP Levels
Abbreviations as in Figure 1.
nivariate Predictors of LVDSDTable 2 Univariate Predictors of LVDSD
Derivati
OR (95% CI)
Age 70 yrs 1.9 (1.4–7.2)
Exercise capacity 9 METs 1.09 (0.78–7.85)
Ejection fraction 68% 2.0 (1.27–11.8)
Atrial fibrillation 2.2 (1.4–8.9)
NFL 2.3 (1.5–13.6)
BNP 105 pg/ml 4.8 (2.5–11.8)
End-diastolic diameter/BSA 35 mm/m2 2.2 (1.7–14.3)
End-systolic diameter/BSA 22 mm/m2 3.6 (2.1–10.4)
Regurgitant volume 65 ml/beat 2.7 (1.3–10.2)
EROA 55 mm2 4.4 (2.2–10.7)
AV/BSA 70 cm3/m2 2.4 (1.7–11.2)
Pulmonary artery systolic pressure 35 mm Hg 1.92 (1.47–9.47)F  atrial fibrillation; CI  confidence interval; LVDSD  left ventricular dysfunction, symptoms of congWhen we entered all markers in the logistic model as
ategorical variables, BNP 105 pg/ml was the strongest
ndependent predictor of LVDSD with an OR: 4.6; 95%
I: 2.7 to 11.6, p 0.0001. Other independent prognostic
ariables were: end-systolic diameter/BSA 22 mm/m2
OR: 3.4; 95% CI: 1.6 to 10.7, p  0.01), and EROA 55
m2 (OR: 4.2, 95% CI: 2.1 to 11.4, p  0.001) (Table 3).
In the validation set, multivariate analysis determined
hat the following variables were independent predictors:
NP 105 pg/ml (OR: 4.1; 95% CI: 2.7 to 12.6, p 
.0001), EROA 55 mm2 (OR: 3.7, 95% CI: 2.4 to 11.9,
 0.001), and end-systolic diameter/BSA 22 mm/m2
HR: 3.1, 95% CI: 1.8 to 13.7, p  0.02); Hosmer-
emeshow test, p  0.147 (Table 3).
The addition of BNP to the non-BNP model (EROA,
nd-systolic diameter/BSA, and AV) significantly increased
he area under the ROC curve from 0.80 to 0.91 (p  0.01)
(n  167) Validation Set (n  102)
p Value OR (95% CI) p Value
0.02 1.4 (1.1–8.2) 0.04
0.19 1.02 (0.58–10.2) 0.25
0.036 2.1 (1.21–12.8) 0.035
0.02 2.2 (1.5–9.4) 0.02
0.01 2.2 (1.3–14.5) 0.01
0.0001 4.4 (2.1–12.8) 0.0001
0.01 2.0 (1.5–13.4) 0.02
0.001 3.4 (1.7–11.5) 0.001
0.01 2.4 (1.2–13.1) 0.03
0.0001 4.7 (2.4–11.7) 0.0001
0.01 2.3 (1.3–14.1) 0.02
0.03 1.7 (1.27–10.2) 0.035on Setestive heart failure, or death; OR  odds ratio; other abbreviations as in Table 1.
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BNP and Asymptomatic Severe MR September 15, 2009:1099–106n the derivation set and from 0.79 to 0.89 (p 0.01) in the
alidation set (Fig. 3).
erial BNP measurements. Patients who reached an end
oint had a higher rate of increase in BNP levels at 1 year
han patients with an uneventful course (rate of increase of
6  11 pg/ml vs. 9  4 pg/ml, p  0.0001, in the
erivation set, and 23  10 pg/ml vs. 8  4 pg/ml, p 
.001, in the validation set).
Among patients with baseline BNP values below 105
g/ml, 5 (3%) exhibited a BNP elevation above that level at
year in the derivation set, and 4 patients (5.3%) did so in
ultivariate Analysis to Predict theombined End Point (Derivat on Set)Table 3 Multivariat Analysis to Predict theCombined End Point (Derivation Set)
OR (95% CI) p Value
BNP 105 pg/ml 4.6 (2.7–11.6) 0.0001
End-systolic diameter/BSA 22 mm/m2 3.4 (1.6–10.7) 0.01
EROA 55 mm2 4.2 (2.1–11.4) 0.001
NP  brain natriuretic peptide; other abbreviations as in Tables 1 and 2.
Figure 3 Receiver-Operator Curve Analysis
Incremental value of BNP 105 pg/ml when added to echocardiographic variables
AV  atrial volume; EROA  effective regurgitant orifice area; ESD/BSA  end-syshe validation set. All of these patients had LVDSD at
ollow-up.
By Kaplan-Meier analysis, patients with an increased
NP over 105 pg/ml at 1 year had a worse outcome than
atients who persisted with BNP 105 pg/ml (log-rank
est: 19.2, adjusted HR: 9.6; 95% CI: 4.9 to 26.6, p 
.0001). Similar findings were observed in the validation set
log-rank test: 17.8, adjusted HR: 9.6; 95% CI: 3.9 to 21.3,
 0.0001).
iscussion
he main conclusion of this study is that in asymptomatic
atients with severe organic mitral regurgitation and no
mpairment in left ventricular function, BNP level at base-
ine has independent prognostic importance.
Our study also confirms that in this type of patient,
chocardiographic parameters such as end-systolic diameter
nd EROA are also independent predictors of adverse out-
ome. However, according to our results, BNP is an even
e prediction of LVDSD (A: derivation and B: validation set).
iameter corrected by body surface area; other abbreviations as in Figures 1 and 2.for th
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September 15, 2009:1099–106 BNP and Asymptomatic Severe MRtronger prognostic marker than end-systolic diameter or
ROA and contributes independent prognostic information
dditional to that provided by these echocardiographic param-
ters. As shown, after the addition of BNP to the echocardio-
raphic model, the area under the ROC curve increased
ignificantly both in the derivation and the validation set.
Furthermore, we determined and validated an optimal
utoff point for BNP of 105 pg/ml, thereby identifying
symptomatic patients with severe mitral regurgitation and
reserved left ventricular systolic function who are at higher
isk. In our study, BNP 105 pg/ml predicted the appear-
nce of LVDSD with additional information barely affected
y the adjustments for end-systolic diameter and EROA.
Another point to consider is the value of the repeated
easurements of BNP. Patients with a greater BNP in-
rease at 1 year had a worse subsequent course.
Why are these findings of clinical importance? As admit-
ed by current guidelines, patients with severe mitral regur-
itation complicated with heart failure or left ventricular
ystolic dysfunction carry a severe prognosis and should be
romptly referred for surgical treatment. Conversely, early
urgery is controversial in asymptomatic patients with nor-
al left ventricular function because this group is considered
o be at low risk. However, our findings indicate that this
roup includes patients with a heterogeneous prognosis,
ome of whom are at higher risk and cannot be identified
sing current risk stratification schemes. Moreover, other
tudies by our group performed in a similar population have
lso shown that these patients are at high risk for an adverse
utcome, as evidenced by a rate of LVDSD of 6.7%/year
7). This high rate of progression in a short-term follow-up
mphasizes the need for improvement of the current risk
tratification schemes.
Because there is a paucity of clinical predictors for the
rognostic assessment of these patients, risk stratification
elies almost exclusively on echocardiographic measure-
ents. Our data led us to conclude that the addition of
NP measurements to the echocardiographic predictors
ould improve risk stratification and facilitate the early and
imely indication of valve surgery.
This is an important clinical objective. In this subset of
symptomatic patients, nonrandomized studies demon-
trated that the strategy of early surgery was associated with
n improvement in the long-term event rate by decreasing
ardiac mortality and the incidence of episodes of congestive
eart failure requiring hospitalization (20,21). Early surgery
an avoid the appearance of major complications, but can
lso improve post-operative results. It has been reported
hat once symptoms or left ventricular dysfunction develop,
ost-operative outcome becomes worse at medium- and
ong-term follow-up (22).
Which are the mechanisms responsible for the prognostic
ignificance of elevated BNP in this particular group of
atients? As determined in previous studies (7,8), end-
ystolic diameter and the EROA entail prognostic value,
robably because they reflect ventricular overload and the vonsequences of valve disease progression (7,8). In our
tudy, these parameters also showed independent prognostic
alue, but the prognostic value of BNP was independent and
dditional to these parameters. This finding suggests that
NP is not merely a surrogate of the consequences of mitral
egurgitation.
Other investigations concluded that natriuretic peptides
oorly correlate with diastolic and systolic diameters
r  0.26 and r  0.16, respectively), EROA (r  0.17),
nd the left atrial volume (r  0.5) (23,24).
Several efforts have been made to identify a parameter
ble to demonstrate ventricular dysfunction, which is not so
vident by classical noninvasive methods (23,25). In exper-
mental models, the transition from compensated to decom-
ensated ventricular function increases the synthesis and
ecretion of BNP (26). Experimental and clinical data
einforce the hypothesis that higher BNP levels in patients
ith preserved left ventricular function at rest could repre-
ent subclinical ventricular dysfunction (26,27). Thus, these
ata led us to speculate that the elevations of this peptide in
symptomatic patients may indicate the presence of subtle
yocardial impairment elicited by longstanding volume
verload.
Few studies have evaluated the relation between BNP and
linical events in organic mitral regurgitation, and to date,
here is a lack of information regarding its usefulness in
symptomatic patients (24,28).
Sutton et al. (29) concluded that natriuretic peptides
ould be useful to determine prognosis in asymptomatic
atients with severe mitral regurgitation. Also, this study
emonstrated that natriuretic peptide levels were higher in
symptomatic patients than in normal controls (29).
Detaint et al. (24) concluded that elevated BNP levels are
ndependently associated with higher mortality rates and the
ombined end point of death or heart failure. A cutoff value
f BNP 31 pg/ml was also established that identified
atients with lower survival rates and higher rates of death
nd CHF.
There are important differences between our investigation
nd that of Detaint et al. (24). First, all patients in our study
ere asymptomatic, whereas in their study a significant
umber of patients with clinical symptoms of heart failure
ere included. Second, we established a cutoff value of BNP
y prospective validation in a separate cohort. Most impor-
ant, in their study group, mitral regurgitation was severe in
nly 35% of patients, whereas in our study group, all
atients had severe mitral regurgitation.
tudy limitations. This study shows the association of
NP with the combined end point of heart failure, left
entricular systolic dysfunction, or death. We focused on the
ajor consequences of severe mitral regurgitation, but a
ost/benefit analysis of the BNP-based strategy and also
urther outcome analysis should be performed.
Among the confounders of the association of interest, we
ave not included the end-systolic and -diastolic ventricular
olumes because they are part of the ejection fraction formula.
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BNP and Asymptomatic Severe MR September 15, 2009:1099–106We believe that the lack of tissue Doppler measurements
s another limitation of this study. Additionally, exercise
tress echocardiography was not performed in our study,
nd recent studies comparing the results of such tests to
rogression of BNP levels indicate its prognostic value
30,31).
Finally, we should mention that the model could be
verfitted when applied to the validation set.
onclusions
n asymptomatic patients with severe mitral regurgitation
nd preserved left ventricular function, risk stratification for
dentification of surgical candidates is controversial. In this
ontext, the identification of a reliable prognostic marker is
f clinical relevance to facilitate the identification of patients
ho could benefit from early and timely surgery.
Because of its independent and incremental prognostic
alue, BNP assessment should be considered in the clinical
outine workup to risk stratify this group of patients.
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